Genelux and Newsoara Announce Collaboration and License Agreement for Oncolytic Immunotherapies

WESTLAKE VILLAGE, Calif.: WESTLAKE VILLAGE, Calif., Sept. 28, 2021 /PRNewswire/ -- Genelux Corporation, a clinical-stage immunotherapy company, and Newsoara BioPharma Co., Ltd., today announced a collaboration and exclusive license for the development and commercialization of Olvi-Vec and other oncolytic viruses. According to the terms of the agreement, Newsoara shall have...

Click to view original post